Standard

Preoperative embolization and local hemostatic agents in palliative decompression surgery for spinal metastases of renal cell carcinoma. / Zaborovskii, Nikita; Ptashnikov, Dmitrii; Mikaylov, Dmitrii; Masevnin, Sergei; Smekalenkov, Oleg.

In: European Journal of Orthopaedic Surgery and Traumatology, Vol. 28, No. 6, 2018, p. 1047-1052.

Research output: Contribution to journalArticlepeer-review

Harvard

Zaborovskii, N, Ptashnikov, D, Mikaylov, D, Masevnin, S & Smekalenkov, O 2018, 'Preoperative embolization and local hemostatic agents in palliative decompression surgery for spinal metastases of renal cell carcinoma', European Journal of Orthopaedic Surgery and Traumatology, vol. 28, no. 6, pp. 1047-1052. https://doi.org/10.1007/s00590-018-2162-6

APA

Zaborovskii, N., Ptashnikov, D., Mikaylov, D., Masevnin, S., & Smekalenkov, O. (2018). Preoperative embolization and local hemostatic agents in palliative decompression surgery for spinal metastases of renal cell carcinoma. European Journal of Orthopaedic Surgery and Traumatology, 28(6), 1047-1052. https://doi.org/10.1007/s00590-018-2162-6

Vancouver

Zaborovskii N, Ptashnikov D, Mikaylov D, Masevnin S, Smekalenkov O. Preoperative embolization and local hemostatic agents in palliative decompression surgery for spinal metastases of renal cell carcinoma. European Journal of Orthopaedic Surgery and Traumatology. 2018;28(6):1047-1052. https://doi.org/10.1007/s00590-018-2162-6

Author

Zaborovskii, Nikita ; Ptashnikov, Dmitrii ; Mikaylov, Dmitrii ; Masevnin, Sergei ; Smekalenkov, Oleg. / Preoperative embolization and local hemostatic agents in palliative decompression surgery for spinal metastases of renal cell carcinoma. In: European Journal of Orthopaedic Surgery and Traumatology. 2018 ; Vol. 28, No. 6. pp. 1047-1052.

BibTeX

@article{dc4b4a1cc2584c57a5cecf2a1e7f2cc0,
title = "Preoperative embolization and local hemostatic agents in palliative decompression surgery for spinal metastases of renal cell carcinoma",
abstract = "BACKGROUND: Intraoperative hemorrhage can sometimes be massive in patients with spinal metastasis of renal cell carcinoma (MRCC). Preoperative embolization and local hemostatic agents are routinely use in spinal tumor surgery, but there have been no comparisons between these methods. This report compares the efficiency of various methods of bleeding control and their influence on outcome and survival after decompression procedures for MRCC.MATERIALS AND METHODS: This was a retrospective case-control study of 54 patients with hypervascular extraosseous MRCC. All patients underwent palliative decompression procedures. We compared two groups of patients stratified by methods of bleeding control. The first group (EMB) included 32 patients who underwent preoperative embolization of a tumor. The second group (HEM) consisted of 22 patients, treated surgically using intraoperative local hemostatic agents. The parameters under evaluation were blood loss volume, drainage loss, possible complications, time of hospital stay and survival.RESULTS: The median intraoperative blood loss for EMB group [1275 (95% CI 1175-1500) mL] was slightly less than the median in HEM group [1400 (95% CI 1050-1725) mL] without significant differences (p = 0.681). The postoperative drainage loss in HEM group [250 (95% CI 140-325) mL] was significantly less than that in EMB group [500 (95% CI 425-550) mL] (p = 0.013). The complication rate (infections, hematomas, neurological deficit) was nearly equal in all groups. No statistically significant difference in overall survival was found between groups: EMB-26 months (1 year-93.3%, 3 years-26.7%) and HEM-24 months (1 year-95.2%, 3 years-16.3%) (p = 0.360).CONCLUSION: Our results suggest that not all patients with MRCC require preoperative embolization, because usage of modern hemostatic agents can be an alternative bleeding control method.",
keywords = "Carcinoma, Renal Cell/secondary, Decompression, Surgical/adverse effects, Embolization, Therapeutic/methods, Female, Hemostasis, Surgical/methods, Hemostatics/administration & dosage, Humans, Kidney Neoplasms/pathology, Male, Middle Aged, Palliative Care, Preoperative Care, Retrospective Studies, Spinal Neoplasms/secondary, Treatment Outcome",
author = "Nikita Zaborovskii and Dmitrii Ptashnikov and Dmitrii Mikaylov and Sergei Masevnin and Oleg Smekalenkov",
year = "2018",
doi = "10.1007/s00590-018-2162-6",
language = "English",
volume = "28",
pages = "1047--1052",
journal = "European Journal of Orthopaedic Surgery and Traumatology",
issn = "1633-8065",
publisher = "Springer Nature",
number = "6",

}

RIS

TY - JOUR

T1 - Preoperative embolization and local hemostatic agents in palliative decompression surgery for spinal metastases of renal cell carcinoma

AU - Zaborovskii, Nikita

AU - Ptashnikov, Dmitrii

AU - Mikaylov, Dmitrii

AU - Masevnin, Sergei

AU - Smekalenkov, Oleg

PY - 2018

Y1 - 2018

N2 - BACKGROUND: Intraoperative hemorrhage can sometimes be massive in patients with spinal metastasis of renal cell carcinoma (MRCC). Preoperative embolization and local hemostatic agents are routinely use in spinal tumor surgery, but there have been no comparisons between these methods. This report compares the efficiency of various methods of bleeding control and their influence on outcome and survival after decompression procedures for MRCC.MATERIALS AND METHODS: This was a retrospective case-control study of 54 patients with hypervascular extraosseous MRCC. All patients underwent palliative decompression procedures. We compared two groups of patients stratified by methods of bleeding control. The first group (EMB) included 32 patients who underwent preoperative embolization of a tumor. The second group (HEM) consisted of 22 patients, treated surgically using intraoperative local hemostatic agents. The parameters under evaluation were blood loss volume, drainage loss, possible complications, time of hospital stay and survival.RESULTS: The median intraoperative blood loss for EMB group [1275 (95% CI 1175-1500) mL] was slightly less than the median in HEM group [1400 (95% CI 1050-1725) mL] without significant differences (p = 0.681). The postoperative drainage loss in HEM group [250 (95% CI 140-325) mL] was significantly less than that in EMB group [500 (95% CI 425-550) mL] (p = 0.013). The complication rate (infections, hematomas, neurological deficit) was nearly equal in all groups. No statistically significant difference in overall survival was found between groups: EMB-26 months (1 year-93.3%, 3 years-26.7%) and HEM-24 months (1 year-95.2%, 3 years-16.3%) (p = 0.360).CONCLUSION: Our results suggest that not all patients with MRCC require preoperative embolization, because usage of modern hemostatic agents can be an alternative bleeding control method.

AB - BACKGROUND: Intraoperative hemorrhage can sometimes be massive in patients with spinal metastasis of renal cell carcinoma (MRCC). Preoperative embolization and local hemostatic agents are routinely use in spinal tumor surgery, but there have been no comparisons between these methods. This report compares the efficiency of various methods of bleeding control and their influence on outcome and survival after decompression procedures for MRCC.MATERIALS AND METHODS: This was a retrospective case-control study of 54 patients with hypervascular extraosseous MRCC. All patients underwent palliative decompression procedures. We compared two groups of patients stratified by methods of bleeding control. The first group (EMB) included 32 patients who underwent preoperative embolization of a tumor. The second group (HEM) consisted of 22 patients, treated surgically using intraoperative local hemostatic agents. The parameters under evaluation were blood loss volume, drainage loss, possible complications, time of hospital stay and survival.RESULTS: The median intraoperative blood loss for EMB group [1275 (95% CI 1175-1500) mL] was slightly less than the median in HEM group [1400 (95% CI 1050-1725) mL] without significant differences (p = 0.681). The postoperative drainage loss in HEM group [250 (95% CI 140-325) mL] was significantly less than that in EMB group [500 (95% CI 425-550) mL] (p = 0.013). The complication rate (infections, hematomas, neurological deficit) was nearly equal in all groups. No statistically significant difference in overall survival was found between groups: EMB-26 months (1 year-93.3%, 3 years-26.7%) and HEM-24 months (1 year-95.2%, 3 years-16.3%) (p = 0.360).CONCLUSION: Our results suggest that not all patients with MRCC require preoperative embolization, because usage of modern hemostatic agents can be an alternative bleeding control method.

KW - Carcinoma, Renal Cell/secondary

KW - Decompression, Surgical/adverse effects

KW - Embolization, Therapeutic/methods

KW - Female

KW - Hemostasis, Surgical/methods

KW - Hemostatics/administration & dosage

KW - Humans

KW - Kidney Neoplasms/pathology

KW - Male

KW - Middle Aged

KW - Palliative Care

KW - Preoperative Care

KW - Retrospective Studies

KW - Spinal Neoplasms/secondary

KW - Treatment Outcome

U2 - 10.1007/s00590-018-2162-6

DO - 10.1007/s00590-018-2162-6

M3 - Article

C2 - 29525980

VL - 28

SP - 1047

EP - 1052

JO - European Journal of Orthopaedic Surgery and Traumatology

JF - European Journal of Orthopaedic Surgery and Traumatology

SN - 1633-8065

IS - 6

ER -

ID: 87883058